Physalaemin

Jump to: navigation, search
Template:Chembox E number
Physalaemin
Identifiers
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
MeSH Physalaemin
Properties
C58H84N14O16S
Molar mass 1265.44 g/mol
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)

Infobox disclaimer and references

WikiDoc Resources for Physalaemin

Articles

Most recent articles on Physalaemin

Most cited articles on Physalaemin

Review articles on Physalaemin

Articles on Physalaemin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Physalaemin

Images of Physalaemin

Photos of Physalaemin

Podcasts & MP3s on Physalaemin

Videos on Physalaemin

Evidence Based Medicine

Cochrane Collaboration on Physalaemin

Bandolier on Physalaemin

TRIP on Physalaemin

Clinical Trials

Ongoing Trials on Physalaemin at Clinical Trials.gov

Trial results on Physalaemin

Clinical Trials on Physalaemin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Physalaemin

NICE Guidance on Physalaemin

NHS PRODIGY Guidance

FDA on Physalaemin

CDC on Physalaemin

Books

Books on Physalaemin

News

Physalaemin in the news

Be alerted to news on Physalaemin

News trends on Physalaemin

Commentary

Blogs on Physalaemin

Definitions

Definitions of Physalaemin

Patient Resources / Community

Patient resources on Physalaemin

Discussion groups on Physalaemin

Patient Handouts on Physalaemin

Directions to Hospitals Treating Physalaemin

Risk calculators and risk factors for Physalaemin

Healthcare Provider Resources

Symptoms of Physalaemin

Causes & Risk Factors for Physalaemin

Diagnostic studies for Physalaemin

Treatment of Physalaemin

Continuing Medical Education (CME)

CME Programs on Physalaemin

International

Physalaemin en Espanol

Physalaemin en Francais

Business

Physalaemin in the Marketplace

Patents on Physalaemin

Experimental / Informatics

List of terms related to Physalaemin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Physalaemin is a tachykinin peptide obtained from the Physalaemus frog, closely related to substance P. Its structure was first elucidated in 1964.[1][2]

Like all tachykinins, physalaemin is a sialagogue (increases salivation) and a potent vasodilator with hypotensive effects.[3]

References

  1. Erspaemer V, Anastasi A, Bertaccini G, Cei JM (1964). "Structure and pharmacological actions of physalaemin, the main active polypeptide of the skin of Physalaemus fuscumaculatus". Experientia. 20 (9): 489–90. PMID 5857249.
  2. Anastasi A, Erspamer V, Cei JM (1964). "Isolation and amino acid sequence of physalaemin, the main active polypeptide of the skin of Physalaemus fuscumaculatus". Arch Biochem Biophys. 108: 341–8. PMID 14240587.
  3. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V (2002). "The tachykinin peptide family". Pharmacol Rev. 54 (2): 285–322. PMID 12037144. Free full text


Cost Effectiveness of Physalaemin

| group5 = Clinical Trials Involving Physalaemin | list5 = Ongoing Trials on Physalaemin at Clinical Trials.govTrial results on PhysalaeminClinical Trials on Physalaemin at Google


| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Physalaemin | list6 = US National Guidelines Clearinghouse on PhysalaeminNICE Guidance on PhysalaeminNHS PRODIGY GuidanceFDA on PhysalaeminCDC on Physalaemin


| group7 = Textbook Information on Physalaemin | list7 = Books and Textbook Information on Physalaemin


| group8 = Pharmacology Resources on Physalaemin | list8 = AND (Dose)}} Dosing of PhysalaeminAND (drug interactions)}} Drug interactions with PhysalaeminAND (side effects)}} Side effects of PhysalaeminAND (Allergy)}} Allergic reactions to PhysalaeminAND (overdose)}} Overdose information on PhysalaeminAND (carcinogenicity)}} Carcinogenicity information on PhysalaeminAND (pregnancy)}} Physalaemin in pregnancyAND (pharmacokinetics)}} Pharmacokinetics of Physalaemin


| group9 = Genetics, Pharmacogenomics, and Proteinomics of Physalaemin | list9 = AND (pharmacogenomics)}} Genetics of PhysalaeminAND (pharmacogenomics)}} Pharmacogenomics of PhysalaeminAND (proteomics)}} Proteomics of Physalaemin


| group10 = Newstories on Physalaemin | list10 = Physalaemin in the newsBe alerted to news on PhysalaeminNews trends on Physalaemin


| group11 = Commentary on Physalaemin | list11 = Blogs on Physalaemin

| group12 = Patient Resources on Physalaemin | list12 = Patient resources on PhysalaeminDiscussion groups on PhysalaeminPatient Handouts on PhysalaeminDirections to Hospitals Treating PhysalaeminRisk calculators and risk factors for Physalaemin


| group13 = Healthcare Provider Resources on Physalaemin | list13 = Symptoms of PhysalaeminCauses & Risk Factors for PhysalaeminDiagnostic studies for PhysalaeminTreatment of Physalaemin

| group14 = Continuing Medical Education (CME) Programs on Physalaemin | list14 = CME Programs on Physalaemin

| group15 = International Resources on Physalaemin | list15 = Physalaemin en EspanolPhysalaemin en Francais

| group16 = Business Resources on Physalaemin | list16 = Physalaemin in the MarketplacePatents on Physalaemin

| group17 = Informatics Resources on Physalaemin | list17 = List of terms related to Physalaemin


}}



Linked-in.jpg